The FRED-X Flow Diverter-An Australian Experience

Area of Science:

• Neuroendovascular therapy
• Medical device technology
• Cerebrovascular disease management

Background:

• The FRED X flow diverter incorporates an antithrombotic surface treatment to mitigate thrombogenicity.
• Intracranial aneurysms pose significant risks, necessitating effective treatment strategies.

Purpose of the Study:

• To evaluate the safety and efficacy of the FRED X flow diverter for treating intracranial aneurysms.
• To assess outcomes in the Australian neurovascular context.

Main Methods:

• Retrospective review of clinical, procedural, and imaging data from a single Australian center.
• Inclusion of 39 patients with 52 aneurysms treated between June 2021 and September 2024.
• Follow-up imaging utilizing MRA and IV-DSA.

Main Results:

• High technical success with 98% satisfactory wall apposition.
• Complete aneurysm occlusion achieved in 74% of cases at median 28-week follow-up; 86% had adequate occlusion (> 90%).
• Low rates of thrombotic complications (rare) and adverse events (10% minor, 5% major); 5% mortality in ruptured cases.

Conclusions:

• FRED X demonstrates favorable safety and efficacy for intracranial aneurysm treatment in Australia.
• High occlusion rates and rare thrombotic events suggest potential benefits of the antithrombotic coating.
• Further large-scale studies with extended follow-up are warranted to confirm these findings.